( December 3, 2025, 2:15 PM EST) -- NEW ORLEANS — The manufacturer of a chemotherapy drug that allegedly caused eye injuries had “newly acquired information” about the risk and could have changed its label under the U.S. Food and Drug Administration’s changes-being-effected (CBE) regulation, the Louisiana federal judge overseeing multidistrict litigation ruled, denying a motion by the drugmaker for summary judgment on preemption grounds....